Preoperative therapy in breast cancer: Lessons from the treatment of locally advanced disease

Antonio C Wolff, Nancy E. Davidson

Research output: Contribution to journalArticle

Abstract

The greater use of screening has changed the stage distribution of breast cancer, and an increasing number of patients are diagnosed with earlier stages of the disease. Still, locally advanced breast cancer (LABC) remains a major clinical problem in the United States and a common presentation in many parts of the world. There is no standard definition of LABC. One commonly used includes patients with large primary tumors greater than 5 cm (T3) or with skin/chest wall involvement (T4), and/or fixed axillary (N2) or ipsilateral internal mammary (N3) lymph node involvement. According to the tumor node metastasis staging, these usually include stage IIIa (T0-2N2 or T3N1-2) and stage IIIb (T4Nx or TxN3) disease. Inflammatory breast cancer (T4d) is included in most classifications despite its distinct clinical behavior and worse prognosis overall, but it serves as an example of combined modality intervention. Historically, the term LABC has been applied to those clinical presentations where the disease is considered inoperable. However, these therapeutic principles (including preoperative or primary systemic therapy [PST]) are increasingly being applied to patients presenting with tumors greater than 5 cm and negative lymph nodes (stage IIb-T3N0) or even smaller tumors, who are considered to have operable disease and a better outcome than those traditionally classified as having LABC. PST is increasingly being used in otherwise operable stage I and II patients aiming at greater rates of breast conservation and earlier efficacy assessment. This article reviews many of these issues and ongoing research questions.

Original languageEnglish (US)
Pages (from-to)239-245
Number of pages7
JournalOncologist
Volume7
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Breast Neoplasms
Neoplasms
Breast
Lymph Nodes
Inflammatory Breast Neoplasms
Therapeutics
Thoracic Wall
Neoplasm Metastasis
Skin
Research

Keywords

  • Locally advanced disease
  • Neoadjuvant theraphy
  • Preoperative theraphy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Preoperative therapy in breast cancer : Lessons from the treatment of locally advanced disease. / Wolff, Antonio C; Davidson, Nancy E.

In: Oncologist, Vol. 7, No. 3, 2002, p. 239-245.

Research output: Contribution to journalArticle

@article{f6e90b4ca29849eab1852566bc97b90f,
title = "Preoperative therapy in breast cancer: Lessons from the treatment of locally advanced disease",
abstract = "The greater use of screening has changed the stage distribution of breast cancer, and an increasing number of patients are diagnosed with earlier stages of the disease. Still, locally advanced breast cancer (LABC) remains a major clinical problem in the United States and a common presentation in many parts of the world. There is no standard definition of LABC. One commonly used includes patients with large primary tumors greater than 5 cm (T3) or with skin/chest wall involvement (T4), and/or fixed axillary (N2) or ipsilateral internal mammary (N3) lymph node involvement. According to the tumor node metastasis staging, these usually include stage IIIa (T0-2N2 or T3N1-2) and stage IIIb (T4Nx or TxN3) disease. Inflammatory breast cancer (T4d) is included in most classifications despite its distinct clinical behavior and worse prognosis overall, but it serves as an example of combined modality intervention. Historically, the term LABC has been applied to those clinical presentations where the disease is considered inoperable. However, these therapeutic principles (including preoperative or primary systemic therapy [PST]) are increasingly being applied to patients presenting with tumors greater than 5 cm and negative lymph nodes (stage IIb-T3N0) or even smaller tumors, who are considered to have operable disease and a better outcome than those traditionally classified as having LABC. PST is increasingly being used in otherwise operable stage I and II patients aiming at greater rates of breast conservation and earlier efficacy assessment. This article reviews many of these issues and ongoing research questions.",
keywords = "Locally advanced disease, Neoadjuvant theraphy, Preoperative theraphy",
author = "Wolff, {Antonio C} and Davidson, {Nancy E.}",
year = "2002",
doi = "10.1634/theoncologist.7-3-239",
language = "English (US)",
volume = "7",
pages = "239--245",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - Preoperative therapy in breast cancer

T2 - Lessons from the treatment of locally advanced disease

AU - Wolff, Antonio C

AU - Davidson, Nancy E.

PY - 2002

Y1 - 2002

N2 - The greater use of screening has changed the stage distribution of breast cancer, and an increasing number of patients are diagnosed with earlier stages of the disease. Still, locally advanced breast cancer (LABC) remains a major clinical problem in the United States and a common presentation in many parts of the world. There is no standard definition of LABC. One commonly used includes patients with large primary tumors greater than 5 cm (T3) or with skin/chest wall involvement (T4), and/or fixed axillary (N2) or ipsilateral internal mammary (N3) lymph node involvement. According to the tumor node metastasis staging, these usually include stage IIIa (T0-2N2 or T3N1-2) and stage IIIb (T4Nx or TxN3) disease. Inflammatory breast cancer (T4d) is included in most classifications despite its distinct clinical behavior and worse prognosis overall, but it serves as an example of combined modality intervention. Historically, the term LABC has been applied to those clinical presentations where the disease is considered inoperable. However, these therapeutic principles (including preoperative or primary systemic therapy [PST]) are increasingly being applied to patients presenting with tumors greater than 5 cm and negative lymph nodes (stage IIb-T3N0) or even smaller tumors, who are considered to have operable disease and a better outcome than those traditionally classified as having LABC. PST is increasingly being used in otherwise operable stage I and II patients aiming at greater rates of breast conservation and earlier efficacy assessment. This article reviews many of these issues and ongoing research questions.

AB - The greater use of screening has changed the stage distribution of breast cancer, and an increasing number of patients are diagnosed with earlier stages of the disease. Still, locally advanced breast cancer (LABC) remains a major clinical problem in the United States and a common presentation in many parts of the world. There is no standard definition of LABC. One commonly used includes patients with large primary tumors greater than 5 cm (T3) or with skin/chest wall involvement (T4), and/or fixed axillary (N2) or ipsilateral internal mammary (N3) lymph node involvement. According to the tumor node metastasis staging, these usually include stage IIIa (T0-2N2 or T3N1-2) and stage IIIb (T4Nx or TxN3) disease. Inflammatory breast cancer (T4d) is included in most classifications despite its distinct clinical behavior and worse prognosis overall, but it serves as an example of combined modality intervention. Historically, the term LABC has been applied to those clinical presentations where the disease is considered inoperable. However, these therapeutic principles (including preoperative or primary systemic therapy [PST]) are increasingly being applied to patients presenting with tumors greater than 5 cm and negative lymph nodes (stage IIb-T3N0) or even smaller tumors, who are considered to have operable disease and a better outcome than those traditionally classified as having LABC. PST is increasingly being used in otherwise operable stage I and II patients aiming at greater rates of breast conservation and earlier efficacy assessment. This article reviews many of these issues and ongoing research questions.

KW - Locally advanced disease

KW - Neoadjuvant theraphy

KW - Preoperative theraphy

UR - http://www.scopus.com/inward/record.url?scp=0036079286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036079286&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.7-3-239

DO - 10.1634/theoncologist.7-3-239

M3 - Article

C2 - 12065797

AN - SCOPUS:0036079286

VL - 7

SP - 239

EP - 245

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -